1Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide,a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monothe~apy or added to metformin,is primarily as a result of a reduction in fat tissue [J]. Diabetes Obes Metab, 2009,11 (12) : 1163- 1172.
2Tremblay AJ,Lamarche B,Lemelin N,et al. Effect of sitagliptin therapy on postprandial lipoprotein level in patient with type 2 diabetes [J]. Diabetes Obes Metab,2011,13 (4) : 366-373.
3Ross SA,Rafeiro E, Meinicke T,et al. Efficacy and safety of Linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin : a randomized, double-blind, placebo-controlled trial [J]. Curt Med Res Opin,2012,28(9): 1465-1474.
4Blonde L,Dagogo-Jaek S,Banerji MA,et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin:resuhs of the Galiant Trial : a primary care,type 2 diabetes study [J]. Diabetes Obes Metab, 2009,11 (10) : 978-986.
5Matthews DR, Dejager S,Ahren B, et al. Vildagliptin add on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride,with no weight gain:results from a 2 year study [J]. Diabetes Obes Metab,2010,12(9) :780-789.
6Mohan V, Yang W, Son HY , et al. Efficacy and safety of Sitagliptin in the treatment of patients with type 2 diabetes in China,India,and Korea [J]. Diabetes Res Clin Pract, 2009,83 ( 1 ) : 106-116.
7Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase -4 inhibitor, Sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin [J]. Diabetes Obes Metab,2007,9(5):733-745.
8Aschner P,Katzeff HL,Guo H,et al. Efficacy and safety of monotherapy of Sitagliptin compared with mefformin in patients with type 2 diabetes [J]. Diabetes Obes Metab, 2010,12(3) : 252-261.
9Garber A,Henry R,Ratner R,et al. LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD-3Mono) :a randomized,52-week, phsae III ,double-blinded,parallel treatment trial [J]. Lancet, 2009,373 (9662) : 473-481.
10DeFronzo RA, Hissa MN, Garber AJ,et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone [J]. Diabetes Care,2009, 32(9) : 1649-1655.
